Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott, J.D., DeMong, D.E., Greshock, T.J., Basu, K., Dai, X., Harris, J., Hruza, A., Li, S.W., Lin, S.I., Liu, H., Macala, M.K., Hu, Z., Mei, H., Zhang, H., Walsh, P., Poirier, M., Shi, Z.C., Xiao, L., Agnihotri, G., Baptista, M.A., Columbus, J., Fell, M.J., Hyde, L.A., Kuvelkar, R., Lin, Y., Mirescu, C., Morrow, J.A., Yin, Z., Zhang, X., Zhou, X., Chang, R.K., Embrey, M.W., Sanders, J.M., Tiscia, H.E., Drolet, R.E., Kern, J.T., Sur, S.M., Renger, J.J., Bilodeau, M.T., Kennedy, M.E., Parker, E.M., Stamford, A.W., Nargund, R., McCauley, J.A., Miller, M.W.
J. Med. Chem.
